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Abbreviations
CA-4

Combretastatin A-4

CA-4P

Combretastatin A-4 phosphate

DAMA-colchicine N-Deacetyl-N-(2-mercaptoacetyl)-colchicine
GTP

Guanidine triphosphate

LDH

Lactate dehydrogenase

mAb

Monoclonal antibody

MTT

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

NMR

Nuclear magnetic resonance

PBS

Phosphate buffered saline

TMCS

Trimethylchlorosilane
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Abstract
The structure-activity relationships of antiproliferative β-lactams, focusing on modifications at the 4position of the β-lactam ring, is described. Synthesis of this series of compounds was achieved utilizing
the Staudinger and Reformatsky reactions. The antiproliferative activity was assessed in MCF-7 cells,
where the 4-(4-ethoxy)phenyl substituted compound 26 displayed the most potent activity with an IC50
value of 0.22 μM. The mechanism of action was demonstrated to be by inhibition of tubulin. Cell
exposure to combretastatin A-4 and 26 led to arrest of MCF-7 cells in the G2/M phase of the cell cycle
and induction of apoptosis. Additionally, mitotic catastrophe for combretastatin A-4 and for 26 was
demonstrated in breast cancer cells for the first time, as evidenced by the formation of giant,
multinucleated cells.
Keywords
Antiproliferative, azetidinone, β-lactam, combretastatin, mitotic catastrophe, tubulin
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1. Introduction
Microtubules are a component of the mitotic spindle and are essential to the mitotic division of cells.
Tubulin is an α-β heterodimeric protein which is the main constituent of microtubules [1]. Tubulin is
the target of numerous small molecule ligands that act by interfering with microtubule dynamics. These
ligands can be broadly divided into two categories – those that inhibit the formation of the mitotic
spindle and those that inhibit the disassembly of the mitotic spindle once it has formed [2]. Tubulin has
three well-characterised binding sites: the taxane domain, the vinca domain and the colchicine domain
and many compounds interact with tubulin at these known sites. Paclitaxel (Taxol, 1, Figure 1) binds to
tubulin at the taxane site, the vinca alkaloids, including vinblastine (2, Figure 1), bind at the vinca
domain and colchicine (3, Figure 1) binds at the colchicine domain. Paclitaxel and vinblastine are in
clinical use for many types of cancer [3]. Colchicine and podophyllotoxin are colchicine-domain
tubulin-binding agents that are not in clinical use due to problems of toxicity. Colchicine was the first
drug known to bind to tubulin and inhibit microtubule formation as early at the 1930’s [1, 4]. Colchicine
is not used clinically for the treatment of cancer due to gastrointestinal side-effects.14 To date, there is no
clinically approved drug that binds to the colchicine-domain of tubulin and much work continues to be
carried out in this area.

The combretastatins are a group of diaryl stilbenes isolated from the stem wood of the South African
tree Combretum Caffrum. Traditionally, the root bark of Combretum Caffrum was powdered and boiled
and used by the Zulu tribe as a charm for harming an enemy, but there is no written evidence of use of
the plant for treating cancer amongst the indigenous people of Africa.[5] A number of constituent
stilbenes were found to inhibit the growth of cancer cells. Combretastatin A-4 (4, Figure 1)
demonstrated potent antiproliferative activity against a number of human cancer cell lines including
multi-drug resistant cancer cell lines [4]. Stilbene 4 binds to the colchicine domain of tubulin and
induces vascular shutdown within tumours [6]. Clinically, a water-soluble prodrug, combretastatin A-4phosphate (CA4P, fosbretabulin, 5, Figure 1) is under evaluation in phase 3 trials for treatment of
4

anaplastic thyroid cancer and in phase 2 trials for non-small cell lung cancer and platinum-resistant
ovarian cancer [7]. In vivo, in isolated tumour systems, vascular shutdown is seen within 20 minutes of
the start of infusion of 5. At 100 mg/kg, rapid and prolonged blood flow shutdown is evident, and both
human and murine tumour models show extensive necrosis within 24 hours. These effects were also
seen at doses between 25 and 1500 mg/kg, indicating the wide therapeutic window [6]. In addition to 5,
a second structurally related prodrug (6, ombrabulin, Figure 1, a water soluble serine amino acid
prodrug) is in clinical trials [7, 8]. A related analogue from the combretastatin A series, combretastatin
A-1 diphosphate (7, OXi4503, Figure 1), is being evaluated in hepatic and solid tumours as well as acute
myeloid leukaemia [7].

Many conformationally restricted analogues of 4 have been reported, the majority of which replace the
isomerisable cis-double bond in 4 with a heterocycle. Reported heterocyclic CA-4 analogues include
imidazole 8,[9] tetrazole 9 [10] and benzoxepin 10 [11] (Figure 2). The azetidin-2-one (β-lactam) ring
[12] is an alternative scaffold for potent non-isomerisable combretastatin analogues (11 - 13, Figure 2)
[13-16]. Having previously investigated comprehensive structure-activity relationships of these series
with a phenyl-substituted ring at the 3-position of the azetidinone ring, it was of importance to extend
the SAR by investigating a range of aryl substituents at the 4-position. It was also valuable to further
characterise the biochemical effects of both 4 and these β-lactam compounds. Herein we report novel
findings for 4 and related β-lactam analogues in MCF-7 breast cancer cells.

2. Results and discussion
2.1 Chemistry
The design of this series of compounds incorporated a 3,4,5-trimethoxyphenyl ring at the N-1 position
of the β-lactam ring, previously demonstrated to be the optimal substituent at this position [15]. This
mimics the A-ring of 4 (Figure 1). The choice of substituents at the 4-position was based on previously
5

reported potent derivatives of 4. The first step in the synthesis of the required β-lactams was the
formation of the imine precursors 14 - 25. This is achieved by condensation of the appropriately
substituted benzaldehydes and anilines (Scheme 1). The desired imines were obtained in high yields.
Synthesis of β-lactams 27 – 33 and 35 – 37 was carried out using the Staudinger reaction with in situ
generation of a ketene and subsequent reaction with the appropriately substituted imine (Method I,
Scheme 1 and Scheme 2). A modified Staudinger method (method II, Scheme 1) requiring overnight
reaction was used to obtain bromo-containing β-lactam 34 as method I was unsuccessful [17]. Where the
appropriate α-bromoacetate precursor was available, the Reformatsky reaction was used for azetidinone
synthesis (26, Scheme 1, method III). The stereochemistry of the β-lactam product obtained can vary
depending on numerous factors, including the reaction conditions, the order of addition of the reagents
and the substituents present on both the imine and on the acid chloride [18-20]. The X-ray crystal
structure of β-lactam 26 shows the trans arrangement for protons H-3 and H-4 of the β-lactam ring, with
J values of 2 Hz (Figure 3). This trans stereochemistry was observed for all -lactam compounds
synthesised with phenyl rings directly attached to positions 3 and 4 of the ring, as evidenced by the
coupling constants, J3,4 = ~2Hz. No cis isomers were detected in this series, probably due to steric
hindrance between the 3- and 4-positions of the azetidin-2-one ring.
β-Lactams 38, 39 and 40 are diphenyl substituted at the 4-position of the azetidinone ring. The imine
precursors, obtained from the appropriately substituted benzophenones, could not be isolated under
normal reflux conditions in ethanol. It has been noted previously that it is more difficult to synthesise
Schiff bases from ketone precursors such as acetophenone and benzophenone than from less sterically
hindered aldehydes such as para-methoxybenzaldehyde. Anhydrous conditions, lengthy reaction times,
high temperatures and the use of activated molecular sieves are normally required [21]. A number of
different reaction conditions were attempted for these compounds. Reaction of benzophenones with
3,4,5-trimethoxyaniline did not proceed when using 4Å molecular sieves, reflux conditions and
anhydrous toluene [22]. Refluxing with benzene, molecular sieves and sodium bicarbonate also did not
yield any of the desired imine [23]. An alternative, one-pot preparation of β-lactams using titanium (IV)
6

chloride was explored [24]. This method uses half an equivalent of TiCl4 in the condensation of the
appropriate aniline and benzophenone using tri-n-butylamine as the base. Subsequent reaction with the
appropriate acid chloride without isolation of the intermediate imine yielded the desired β-lactams 38,
39 and 40 in low yields.
2.2 Pharmacology and Biochemical results
2.2.1 Antiproliferative activity in breast cancer cells
Compounds 26-40 were screened for their antiproliferative activity in the ER expressing MCF-7 human
breast cancer cell line using the MTT assay [25]. The drug concentration required to inhibit the cell
growth by 50% (IC50) was determined and the results are displayed in Table 1. Additional screening
using the ER independent MDA-MB-231 human breast cancer cell lines was carried out for selected
analogues.
The antiproliferative activity of the 3-phenyl substituted β-lactams in MCF-7 and MDA-MB-231 breast
cancer cells (Table 1) are in general agreement with our previously reported results obtained for a series
of 3-unsubstituted -lactam compounds [14]. β-Lactam 13 was chosen as the lead compound due to
both its synthetic accessibility and the potential to examine a number of related analogues to examine
the structure-activity relationships of derivatives with variations at the 4-position of the β-lactam ring. 4Ethoxy derivate 26 was the most potent compound in this series in MCF-7 cells with an IC50 value of
0.22 μM. This is a decrease in activity of approximately 10-fold compared to 13, and is consistent with
previously reported ethoxy-substituted combretastatin derivatives [26]. Surprisingly 27, the 4-fluoro
compound displays sub-micromolar activity which is not shown in a related 3-unsubstituted compound
previously reported.[14] However, potent fluoro-containing analogues of 4 are known [27]. The 4dimethylamino substituted compound 28 and 3,4-dimethoxyphenyl compound 33 also exhibit
submicromolar activity. The inclusion of the two trimethoxy ring systems (as in compounds 29, 30, 31
and 32) gives less active compounds with antiproliferative values in the high micromolar range
7

regardless of the substitution pattern of the methoxy groups at position 4. A bromine-containing
analogue (34, IC50=1.42μM) was of interest as a derivative of 4 which replaced the hydroxy group of
Ring B with a bromide substituent was reported to have moderate activity in a range of cell lines [28]. In
our series, this compound was not as potent as either the lead compound 13 or 26. However, this
compound has the potential to be used as an intermediate in the synthesis of further boronic acid βlactams, as has been reported for potent boronic acid bioisosteres of 4 [29]. The 2-naphthalene moiety
has been demonstrated to be good surrogate for the B-ring of the combretastatin series [30], and the
equivalent β-lactam 35 containing a 2-naphthalene ring at the 4-position shows submicromolar activity
with an IC50 value of 0.44 μM.
Other aryl substituent variations at the C-4 position were also examined. Removal of the direct
attachment of the phenyl ring to the β-lactam core results in reduction of antiproliferative effect by a
factor of 100 (vinyl analogue 36 has an IC50 value of 1.99 μM compared to 0.034 μM for 13). This is
also true of the N-1 position, where a methylene spacer introduced in compound 37 between the core βlactam ring and the trimethoxyphenyl ring led to a decrease in activity by over a thousand-fold (IC50
value of 38.6 μM compared to 0.034 μM for 13). The introduction of the two phenyl rings at the C-4
position also leads to a reduction in activity with 39 and 40, both of which contain methoxy groups on
one or both phenyl rings, showing antiproliferative effect in the sub-micromolar range and 38 displaying
even lower antiproliferative activity (IC50 = 3.84 µM).
This series of analogues did not display submicromolar antiproliferative activity equipotent with either 4
or 13 in MDA-MB-231 breast cancer cells, with the exception of compounds 26 and 33. Compound 26
displayed an IC50 value of 0.83 μM while 4-(3,4-dimethoxyphenyl) substituted β-lactam 33 had an IC50
value of 0.53 μM which was nearly 10-fold less potent than 13 (Table 2).
The cytotoxicity of selected analogues at 10 µM was determined using an LDH assay. The range of
cytotoxicity in MCF-7 cells was between 3% for 33 and 10.4% cell death for dimethylamino-containing
analogue 28. These values are comparative to the percentage of cell death of 5.5% at 10 µM observed
8

for 4 in MCF-7 cells. In MDA-MB-231 cells, cytotoxicity at 10 µM ranged from 0 % (analogues 27, 30,
31, 32 and 33) to 6.1 % (compound 29), again falling in the same low percentage range as 4 (4.3%). The
cytotoxicity for the most potent compound, 26, was 5.4%. This confirms previous work in normal
murine epithelial cells that both 4 and β-lactam derivatives are minimally cytotoxic to non-proliferating
cells [15, 16].
2.2.2 Tubulin polymerization and immunofluorescence
β-Lactam 26 was chosen for further study on the basis of its potent antiproliferative activity in MCF-7
cells, together with an assessment of its drug-like properties via a Tier 1 profiling screen. Compound 26
satisfies Lipinski’s ‘rule of five’ for drug-like properties e.g. molecular weight (433) is less than 500, the
number of oxygen/nitrogen atoms is less than 10, the number of hydrogen bond donors is less than 5 and
the cLogP value of 3.72 (<5), imply that this is a moderately lipophilic-hydrophobic drug and is a
suitable candidate for further investigation (in addition to predictions of permeability, metabolic
stability, Pgp substrate status, blood-brain barrier partition, plasma protein binding and human intestinal
absorption properties which indicated the suitability of these compounds for further development).
In this study, we investigated the tubulin-targeting properties of 26 by a turbidity assay and confocal
microscopy. As expected, 26 (10 μM) completely inhibited the assembly of tubulin in a cell free tubulin
turbidity assay in a similar manner to that previously reported for 4 (Figure 4) thus confirming that the
target of this series of compounds is tubulin. In an attempt to identify the cellular effects that may be
relevant to the antiproliferative activity of 26, we evaluated their activity on the alteration of the
microtubule network by tubulin immunostaining, comparing it to that of 4. Confocal analysis of MCF-7
cells stained with α-tubulin mAb demonstrated a well organised microtubular network in control cells
(Figure 5). Exposure to 4 (100 nM) or 26 (500 nM) for 16 h led to a complete loss of microtubule
formation consistent with depolymerised microtubules (Figure 5). Additionally, cells treated with 4 and
26 increased in cell size and contained multiple micronuclei - a phenomenon described as mitotic
catastrophe. Mitotic catastrophe is a type of programmed cell death in response to DNA damage,
9

characterised by giant multinucleated cells [31]. These findings are in agreement with previously
published studies, where 5 induced mitotic catastrophe in chronic lymphocytic leukemia cells [32].
Similarly, 4 and a combretastatin derivative induced mitotic catastrophe dependent on spindle
checkpoint and caspase-3 activation in non-small cell lung cancer cells [33, 34]. Mitotic catastrophe has
also been demonstrated for 4 and related derivatives in both human endothelial cells (HUVEC) and
human lung carcinoma cells (H460) [35]. Taken together, these results confirm tubulin as the molecular
target of this series of β-lactam combretastatin derivatives and demonstrate mitotic catastrophe in MCF7 breast cancer cells for 4 and 26 for the first time.
2.2.3 Analysis of DNA content by flow cytometry.
We next examined the effect of 4 and -lactam 26 on the cell cycle of MCF-7 cells by flow cytometric
analysis of propidium iodide stained cells. After 48 h, both 4 and 26 induced a significant increase in the
percentage of cells in the G2M phase of the cell cycle (52% and 47.5% respectively compared to 19.7%
in untreated cells, P=0.02) together with a significant increase in apoptosis as determined by
quantification of the sub-G1 population of cells (9.4% and 13.97% respectively compared to 1.65% in
untreated cells) (Table 3 and Figure 6).
2.3 Structural studies of β-lactam compound 26 in the colchicine-binding site of tubulin
The proposed mode of binding of β-lactam 26 was investigated by virtual molecular docking using a
published crystal structure of DAMA-colchicine (41) bound to the colchicine domain of αβ-tubulin [36].
Figure 7 illustrates the key interactions observed for 41 in the active site of tubulin. It is clear that 41
appears to bind to the interface of the αβ heterodimer of tubulin. The key contacts involved have been
described by Knossow et al with the trimethoxy A-ring of 41 interacting with Cys241.[36] Crosslinking
studies with trimethoxy substituted A-rings with more reactive groups have previously shown the
importance of Cys241 in the binding process [36, 37]. A similar binding orientation is observed for the
trimethoxyphenyl A-rings of 41 and 26 (Figure 7). The positioning of the trimethoxy substituents of the
10

A-rings differ slightly due to the 3D conformation of the molecule but both can still interact favorably
with Cys241 to provide the anchoring interaction in the binding site. These binding parallels may
rationalize the antiproliferative potency observed for 26. The C-ring at the 3-position of the β-lactam is
observed to fill the pocket of tubulin more optimally than in the case of colchicine. This binding
orientation differs from that previously observed for a related series of β-lactams, where the aryl ring at
the C4-position of the β-lactam filled the space occupied by the C-ring of colchicine [15, 16].
Hydrogen bonding between sulfur and Ser178 is also depicted in Figure 7 in both the co-crystal of 41
and also the docked complex of 26 which uses oxygen as a H-bond acceptor in this case. It is likely that
a steric clash between the longer ethoxy side-chain and the residues in the binding site contributes to the
changed binding conformation in comparison to 3, 4 and 13 where the 3-hydroxy-4-methoxyphenyl ring
(or C-4 4-methoxyphenyl ring in the case of 13) occupies the space now occupied by the C-3 phenyl ring
of 26. The difference in positioning of the ethoxy side chain of 26 and the methoxy group of the C-ring
of 41 may be significant for observed antiproliferative activity of 26 in combretastatin-resistant cell lines
(data not shown).
Structurally, similarity between the common features of 3, 4 and antiproliferative β-lactams has been
demonstrated. Of particular note is that the crystal structures of 4 [38], 5 [28], 13[15] and 26 show noncoplanar ring systems. In the crystal structure of the -lactam 26 (figure 3), the distance between the
centroid of the C-3-phenyl and N-1-phenyl rings is 7.338 Å, in comparison to 6.193 Å for the distance
between the centroids of C-3 and C-4 phenyl rings and 5.146 Å between the N-1 and C-4 phenyl rings
(Figure 8). The comparative distance between the centroids of the A- and C-rings of the co-crystal
structure of 41 is 4.516 Å. Surprisingly, the equivalent distance between the centroids of A- and B-rings
of 4 (5.191 Å) is closer in distance to that between N-1 and C-4 of -lactam compound 26, but despite
this, the preferred orientation of 26 in the molecular docking with tubulin showed overlay of the N-1 and
C-3 rings of 26 with the A- and B-rings of 41.
3. Conclusion
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A novel series of antiproliferative agents are described. Structural and molecular modelling studies
rationalize the observed antiproliferative activities. Interesting effects on microtubule dynamics were
observed both for 4 and β-lactam derivative 26, including mitotic catastrophe in MCF-7 breast cancer
cells observed for the first time. MCF-7 breast cancer cells treated with 4 and 26 undergo cell death both
through microtubule disorganization and mitotic catastrophe, as demonstrated by the presence of giant
multinucleated cells. These observations suggest that the activities of 4 and 26 in MCF-7 cells might not
be related solely to a microtubule-damaging mechanism and that additional mechanisms involved in
mitosis control should be considered. The unusual effects of these compounds are significant and are
under further investigation.
4. Experimental Protocols
4.1 Chemistry
All reagents were commercially available and were used without further purification unless otherwise
indicated. Toluene was dried by distillation from sodium and stored on activated molecular sieves (4 Å)
and dichloromethane was dried by distillation from calcium hydride prior to use. IR spectra were
recorded as thin films on NaCl plates or as KBr discs on a Perkin-Elmer Paragon 100 FT-IR
spectrometer. 1H and
oC,

13C

400.13 MHz for

NMR spectra were obtained on a Bruker Avance DPX 400 instrument at 20

1H

spectra, 100.61 MHz for

13C

spectra, in CDCl3 (internal standard

tetramethylsilane) by Dr. John O’Brien and Dr. Manuel Ruether in the School of Chemistry, Trinity
College Dublin. High resolution accurate mass determinations for all final target compounds were
obtained on a Micromass time of flight mass spectrometer (TOF) equipped with electrospray ionization
(ES) interface operated in the positive ion mode at the High Resolution Mass Spectrometry Laboratory
by Dr. Martin Feeney in the School of Chemistry, Trinity College Dublin. Elemental analysis was
carried out in the microanalytical laboratory at University College Dublin, Belfield, Dublin 4. Thin layer
chromatography was performed using Merck Silica gel 60 TLC aluminium sheets with fluorescent
indicator visualizing with UV light at 254 nm. Flash chromatography was carried out using standard
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silica gel 60 (230-400 mesh) obtained from Merck. All products isolated were homogenous on TLC.
Analytical high-performance liquid chromatography (HPLC) to determine the purity of the final
compounds was performed using a Waters 2487 Dual Wavelength Absorbance detector, a Waters 1525
binary HPLC pump, a Waters In-Line Degasser AF, a Waters 717plus Autosampler and a Varian Pursuit
XRs C18 reverse phase 150 x 4.6 mm chromatography column. Samples were detected using a
wavelength of 254 nm. All samples were analyzed using acetonitrile (70%): water (30%) over 10 min
with a flow rate of 1 mL/min. Unless otherwise indicated, the purity of the final products was ≥ 95%.
Analyses indicated by the symbols of the elements or functions were within ± 0.4 % of the theoretical
values.
4.1.1 General preparation of Schiff bases (14 - 25)
A solution of the appropriately substituted aryl aldehyde (0.1 mol) and the appropriately substituted aryl
amine (0.1 mol) in ethanol (50 mL) was heated at reflux for three hours. The reaction mixture was
reduced to 25 mL under vacuum. The mixture was left to stand and the Schiff base product crystallized
out of the solution. The crude product was then recrystallized from ethanol and filtered to yield the
purified product. Schiff bases 15, 17, 19, 20 and 25 was prepared and isolated as previously reported
[14].
N-(4-Ethoxybenzylidene)-3,4,5-trimethoxyaniline

14.

Preparation

was

as

above

from

3,4,5-

trimethoxybenzenamine and 4-ethoxybenzaldehyde. Yield 64 %, yellow crystalline solid, m.p. 98 °C. IR
νmax (KBr): 1604.72 cm-1, 1586.85 cm-1 (-C=N-). 1H NMR (400 MHz, CDCl3) δ 1.43 – 1.47 (t, 3H), 3.86
(s, 3H), 3.90 (s, 6H), 4.08 – 4.13 (m, 2H), 6.47 (s, 2H), 6.97 (d, 2H, J=8.28 Hz), 7.83 (d, 2H, J=8.8 Hz),
8.40 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 14.30, 55.65, 60.58, 63.22, 97.63, 114.23, 128.42, 130.03,
135.58, 147.90, 153.08, 158.74, 161.26. Elemental analysis: C18H21NO4 (C, H, N)
N-(4-(Dimethylamino)benzylidene)-3,4,5-trimethoxyaniline 16. Preparation was as above from 4dimethylaminobenzaldehyde and 3,4,5-trimethoxyaniline. Yield 64 %, yellow crystals, m.p. 83-84 °C. IR
νmax (KBr): 1602.7 cm-1 (C=N). 1H NMR (400 MHz, CDCl3): δ 3.08 (s, 6H, -N-CH3), 3.85 (s, 3H,
13

OCH3), 3.89 (s, 6H, OCH3), 6.47 (s, 2H, ArH), 6.73 (d, 2H, J=9 Hz, ArH), 7.76 (d, 2H, J=9.04 Hz,
ArH), 8.33 (s, 1H, -CH=N). 13C NMR (100 MHz, CDCl3): δ 39.42, 55.42, 55.61, 60.54, 97.64, 111.10,
123.54, 130.01, 135.14, 148.42, 152.08, 152.99, 159.43. HRMS: Calculated for C18H23N2O3: 314.3790;
Found 315.1709 (M++H).
3,4,5-Trimethoxy-N-(2,4,6-trimethoxybenzylidene)aniline 18. Preparation was as above from 2,4,6trimethoxybenzaldehyde and 3,4,5-trimethoxyaniline. Yield 69 %, Orange gel, IR νmax (NaCl film):
1659.4 cm-1 (C=N). 1H NMR (400 MHz, CDCl3): δ 3.86 (s, 3H, OCH3), 3.90 (s, 9H, OCH3), 3.94 (s,
3H, OCH3), 3.96 (s, 3H, OCH3), 6.48 (s, 2H, ArH), 6.52 (s, 1H, ArH), 7.65 (s, 1H, ArH), 8.82 (s, 1H, CH=N).

13C

NMR (100 MHz, CDCl3): δ 56.01, 56.22, 56.38,  60.95, 98.20, 108.84, 116.48, 136.78,

143.55, 148.87, 153.37, 155.04, 155.16.
N-(3-Bromo-4-methoxybenzylidene)-3,4,5-trimethoxyaniline 21. Preparation was as above from 3,4,5trimethoxyaniline and 3-bromo-4-methoxybenzaldehyde. Yield 68 %, Yellow crystalline solid, m.p. 128
°C. IR νmax (KBr): 1620.47 cm-1, 1585.77 cm-1 (-C=N-). 1H NMR (400 MHz, CDCl3) δ 3.89 (s, 3H),
3.92 (s, 6H), 3.99 (s, 3H), 6.50 (s, 2H), 7.00 (d, 1H, J=8.52 Hz), 7.79 – 7.81 (dd, 1H), 8.18 (d, 1H, J=2
Hz), 8.38 (s, 1H).

13C

NMR (100 MHz, CDCl3) δ 55.68, 56.00, 60.59, 97.67, 111.13, 111.95, 129.22,

129.81, 132.82, 135.92, 147.24, 153.13, 157.00, 157.81. HRMS: C17H18NO4Br requires 380.0580;
Found 380.0497; Elemental analysis: C17H18BrNO4 (C, H, N, Br)
3,4,5-Trimethoxy-N-(naphthalen-2-ylmethylene)aniline 22. Preparation was as above from 2naphthaldehyde and 3,4,5-trimethoxyaniline. Yield 77 %, yellow crystals, m.p. 108-116°C. IR νmax
(KBr): 1625.74, 1610.62 and 1583.40 cm-1 (C=N).δ 3.88 (s, 6H, OCH3), 3.93 (s, 3H, OCH3), 6.57–7.25
(m, 9H, ArH), 8.67 (s, 1H, N=CH). Elemental analysis: C20H19NO3 (C, H, N)
3,4,5-Trimethoxy-N-(3-(4-methoxyphenyl)allylidene)aniline 23. Preparation was as above from 3-(4methoxy-phenyl)-propenal and 3,4,5-trimethoxyaniline. Yield 57 %, Yellow crystalline solid, m.p.
128°C. IR νmax (NaCl): 1626.36 cm-1, 1582.90 cm-1 (-C=N-). 1H NMR (400 MHz, CDCl3) δ 3.86 - 3.90
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(m, 12H), 6.48 (s, 2H), 6.93 - 7.02 (m, 3H), 7.12 - 7.16 (m, 1H), 7.50 (d, 1H, J=9.04 Hz), 8.28 (d, 1H,
J=9.04 Hz). HRMS: C19H22NO4 requires 328.1549; Found 328.1545 (M++H).
N-(4-Methoxybenzylidene)-1-(3,4,5-trimethoxyphenyl)methanamine 24. Preparation was as above from
3,4,5-trimethoxybenzylamine and 4-methoxybenzaldehyde. Yield 54 %, Colourless crystals, m.p. 62°C.
IR νmax (KBr): 1630.82, 1603.44 cm-1. 1H NMR (400 MHz, CDCl3) δ 3.85 – 3.88 (m, 12H), 4.74 (s,
2H), 6.60 (s, 2H), 6.97 (d, 2H, J=9.04 Hz), 7.76 (d, 2H, J=8.52 Hz), 8.35 (s, 1H). 13C NMR (100 MHz,
CDCl3) δ 54.93, 55.63, 55.69, 60.39, 64.82, 76.31, 76.63, 76.95, 103.46, 104.44, 113.56, 113.86,
128.55, 129.43, 131.56, 134.87, 136.41, 152.83, 160.87, 161.33. Elemental analysis: C18H21NO4 (C, H,
N)
4.1.2 General methods for preparation of 3-substituted azetidin-2-ones
4.1.2.1 Staudinger reaction (method I): A solution consisting of acetyl chloride (7.5 mmol) in
anhydrous CH2Cl2 (50 mL) was added dropwise to a stirring solution containing the appropriate imine
(5 mmol) and triethylamine (15 mmol) in anhydrous CH2Cl2 (50 mL) at reflux in an inert atmosphere.
The solution was refluxed for 10 hours and then washed with saturated sodium bicarbonate solution (50
mL), dilute (10 %) HCl (50 mL) and brine (50 mL). The organic layer was dried and evaporated in
vacuo.
4.1.2.2 Modified Staudinger reaction (method II): The appropriate imine (10 mmol) and acetyl
chloride (10 mmol) were added to anhydrous CH2Cl2 (50 mL) under nitrogen and the mixture was left
stirring for 2 hours. Triethylamine (10 mmol) was injected dropwise and the mixture was stirred
overnight. The mixture was washed with distilled water (50 mL) (twice) and then with saturated
aqueous sodium bicarbonate solution (50 mL). The organic layer was dried by filtration through
anhydrous sodium sulfate. The organic layer containing the product was collected and reduced in vacuo.
4-(4-Fluorophenyl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 27. Preparation was from 15 (5
mmol) as described in method I. Evaporation of solvent yielded a brown solid residue which was
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purified using column chromatography hexane:diethyl ether (1:1). Yield 11 %, Orange gel. IR νmax
(KBr): 1706.1 cm-1 (C=O, β-lactam). 1H NMR (400 MHz, CDCl3): δ 3.72 (s, 6H, OCH3), 3.78 (s, 3H,
OCH3), 4.26-4.27 (d, 1H, J=2.5 Hz, H3), 4.91-4.92 (d, 1H, J=2.5 Hz, H4), 6.61 (s, 2H, ArH), 7.14 (m,
2H, ArH), 7.31-7.45 (m, 7H, ArH).

13C

NMR (100 MHz, CDCl3): δ 55.57, 60.51, 62.98, 64.66, 94.35,

115.86, 116.07, 126.97, 128.68, 132.80, 133.05, 133.99, 134.17, 153.15, 163.62, 164.88. HRMS:
C24H22FNO4Na requires 430.1430; Found 430.1395 (M++Na).
4-(4-(Dimethylamino)phenyl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 28. Preparation was
from 16 (10 mmol) as described in method I. Evaporation of solvent yielded a brown solid residue
which was purified using column chromatography hexane: diethyl ether (1:1). Yield 6 %, Orange
powder, m.p. 118°C. IR νmax (NaCl film): 1745.1 cm-1 (C=O, β-lactam). 1H NMR (400 MHz, CDCl3): δ
2.99 (s, 6H, N-CH3), 3.75 (s, 6H, OCH3), 3.80 (s, 3H, OCH3), 4.33 (d, 1H, J=2.5 Hz, H3), 4.86, (d, 1H,
J= 2.5 Hz, H4), 6.69 (s, 2H, ArH), 6.76 (d, 2H, J=8.5 Hz, ArH), 7.31-7.33 (m, 2H, ArH), 7.35-7.39 (m,
5H, ArH).

13C

NMR (100 MHz, CDCl3): δ 9.96, 55.55, 55.61, 60.49, 63.81, 64.42, 94.45, 112.26,

123.75, 126.74, 127.32, 127.52, 128.11, 128.32, 128.78, 129.19, 133.51, 134.21, 134.65, 150.34,
153.00, 153.21, 165.59. HRMS: C26H30N2O4 requires 433.5116; Found 433.2112 (M++H).
3-Phenyl-4-(2,3,4-trimethoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 29. Preparation was from
17 (3 mmol) as described in method I. Evaporation of solvent yielded a brown solid residue, which was
purified using column chromatography hexane: diethyl ether (1:1). Yield 10 %, Yellow solid, m.p. 92°C.
IR νmax (NaCl film): 1749.2 cm-1 (C=O, β-lactam). 1H NMR (400 MHz, CDCl3): δ 3.74 (s, 6H, OCH3),
3.77 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.88 (s, 3H, OCH3). δ 4.36 (d, 1H, J=2.5
Hz, H3), 5.22 (d, 1H, J= 2.5 Hz, H4), 6.63 (s, 2H, ArH), 7.05 (d, 1H, J=8.6 Hz, ArH), 7.15 (d, 1H, J=6.5
Hz, ArH), δ 7.25-7.35 (m, 5H, ArH). 13C NMR (100 MHz, CDCl3): δ 55.56, 58.11, 60.40, 60.51, 61.12,
63.39, 94.30, 107.34, 121.07, 126.59, 127.02, 127.30, 128.24, 128.76, 129.58, 130.18, 133.31, 134.55,
135.49, 153.07, 153.60, 160.03, 161.70, 165.46. HRMS: C27H29NO7Na requires 502.1842; Found
502.1823 (M++Na).
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3-Phenyl-4-(2,4,6-trimethoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 30. Preparation was from
18 (3 mmol) as described in method I. Evaporation of solvent yielded a brown solid residue, which was
purified using column chromatography, Hexane: diethyl ether (1:1). Yield 52 %, Yellow solid, m.p. 112114°C. IR νmax (KBr): 1746.6 cm-1 (C=O, β-lactam). 1H NMR (400 MHz, CDCl3): δ 3.73 (s, 3H, OCH3),
3.75 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.86 (s, 6H, OCH3), 4.86 (d, 1H, J=2.5 Hz,
H3), 5.52 (d, 1H, J=2.5 Hz, H4), 6.07 (s, 2H, ArH), 6.64 (s, 2H, ArH), 7.34-7.37 (m, 5H, ArH).

13C

NMR (100 MHz, CDCl3): δ 54.44, 54.89, 55.05, 55.27, 55.48, 55.51, 58.88, 60.42, 89.76, 90.38, 93.72,
105.11, 126.83, 127.09, 128.29, 133.76, 136.13, 152.83, 159.86, 161.36, 163.83, 165.83.
3-Phenyl-1,4-bis(3,4,5-trimethoxyphenyl)azetidin-2-one 31. Preparation was from 25 (3 mmol) as
described in method I. Evaporation of solvent yielded a brown solid residue, which was purified using
column chromatography, DCM:EtOAc (19:1). Yield 7 %, Yellow powder, m.p. 231°C. IR νmax (KBr):
1747.2 cm-1 (C=O, β-lactam). 1H NMR (400 MHz, CDCl3): δ 3.74 (s, 6H, OCH3), 3.79 (s, 3H, OCH3),
3.83 (s, 6H, OCH3), 3.87 (s, 3H, OCH3), 4.31 (d, 1H, J=2.5 Hz, H3), 4.81 (d, 1H, J= 2.5 Hz, H4), 6.62
(d, 4H, J=5 Hz, ArH), 7.34-7.39 (m, 5H, ArH).

13C

NMR (100 MHz, CDCl3): δ 55.60, 55.87, 60.47,

60.53, 64.10, 64.48, 94.42, 102.28, 127.03, 127.58, 128.25, 128.66, 129.05, 133.26, 134.17, 134.19,
153.09, 153.59, 165.20. HRMS: C27H29NO7Na requires 502.1842; Found 502.1849 (M++Na).
3-Phenyl-4-(2,4,5-trimethoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 32. Preparation was from
19 (4 mmol) as described in method I. Evaporation of solvent yielded a brown solid residue, which was
purified using column chromatography, DCM. Yield 6 %, Yellow powder, m.p. 126-128°C. IR νmax
(NaCl film): 1740.0 cm-1 (C=O, β-lactam). 1H NMR (400 MHz, CDCl3): δ 3.74 (s, 6H, OCH3), 3.77 (d,
6H, J=4.52 Hz, OCH3), 3.82 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 4.40 (d, 1H, J=2 Hz, H3), 5.31 (d, 1H,
J= 2 Hz, H4), 6.58 (s, 1H, ArH), 6.66 (s, 2H, ArH), 6.85 (s, 1H, ArH), 7.27-7.35 (m, 5H, ArH).

13C

NMR (100 MHz, CDCl3): δ 55.54, 55.60, 56.02, 56.31, 57.59, 60.52, 61.11, 62.84, 94.25, 96.93,
110.05, 115.65, 126.65, 127.73, 128.23, 129.83, 133.39, 133.92, 134.01, 143.15, 149.56, 151.50,
153.03, 165.64. HRMS: C27H29NO7Na requires 502.1842; Found 502.1835 (M++Na).
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4-(3,4-Dimethoxyphenyl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 33. Preparation was from
20 (4 mmol) as described in method I. Evaporation of solvent yielded a brown solid residue, which was
purified using column chromatography, DCM:EtOAc (19:1). Yield 5 %, Orange solid, m.p. 106-108°C.
IR νmax (NaCl film): 1738.9 cm-1 (C=O, β-lactam). 1H NMR (400 MHz, CDCl3): δ 3.72 (s, 6H, OCH3),
3.78 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 4.31 (d, 1H, J=2.5 Hz, H3), 4.86 (d, 1H,
J=2.5 Hz, H4), 6.63 (s, 2H, ArH), 6.89-6.91 (m, 2H, ArH), 6.99-7.01 (q, 1H, J=2 Hz, 6 Hz, ArH), 7.317.40 (m, 5H, ArH). 13C NMR (100 MHz, CDCl3): δ 55.58, 60.44, 63.68, 64.47, 94.34, 107.90, 111.01,
118.31, 126.94, 127.43, 128.56, 129.31, 133.27, 134.23, 148.94, 149.32, 153.01, 165.21. HRMS:
C26H27NO6Na requires 472.1736; Found 472.1752 (M++Na).
4-(3-Bromo-4-methoxyphenyl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 34. Preparation was
from 21 as described in method II. Yield 3.7 %, Light off-white powder, m.p. 82 ºC. IR νmax (KBr):
1751.57 cm-1 (C=O, β-lactam). 1H NMR (400 MHz, CDCl3) δ 3.77 (s, 6H, OCH3), 3.81 (s, 3H, OCH3),
3.94 (s, 3H, OCH3), 4.29 (d, 1H, J=2 Hz), 4.85 (d, 1H, J=2 Hz), 6.61 (s, 2H, ArH), 6.97 (s, 1H, ArH),
7.34 – 7.41 (m, 6H, ArH), 7.64 (s, 1H, ArH). 13C NMR (400 MHz, CDCl3) δ 55.65, 55.92, 60.53, 62.64,
64.65, 94.39, 111.98, 112.09, 125.68, 126.97, 127.63, 128.68, 130.47, 130.62, 133.03, 133.95, 153.16,
155.79, 164.89. HRMS: C25H24BrNO5 requires 498.0916; Found 498.0926 (M++H).
4-(Naphthalen-2-yl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 35. Preparation was from 22 as
described in method I. Yield 5.4 %, IR νmax (KBr): 1751.19 cm-1 (C=O, β-lactam). 1H NMR (400 MHz,
CDCl3): δ 3.70-3.78 (9H, OCH3), 4.41 (m, 1H, H3), 5.11 (m, 1H, H4), 6.61 (s, 2H, ArH), 7.29-7.96 (m,
12H, ArH). 13C NMR (400 MHz, CDCl3): δ 56.06, 60.96, 64.38, 65.06, 94.89, 122.96, 134.97, 153.59,
165.58. HRMS: C28H25NO4Na requires 462.1681; Found 462.1673 (M++Na).
(4-(4-Methoxystyryl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 36. Preparation was from 23 as
described in method I. Yield 6 %, Yellow oil. IR νmax (NaCl film): 1747.40 cm-1 (C=O, β-lactam). 1H
NMR (400 MHz, CDCl3) δ 3.82 – 3.85 (m, 12H, OCH3), 4.31 (d, 1H, J=1.5 Hz, H3), 4.58 – 4.60 (m,
1H, H4), 6.26 – 6.32 (m, 1H, ArH), 6.81 – 6.85 (t, 3H), 6.90 (d, 2H, J=8.5 Hz), 7.37 – 7.39 (m, 7H). 13C
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NMR (400 MHz, CDCl3) δ 54.91, 55.65, 60.57, 61.76, 63.28, 94.22, 113.76, 123.98, 127.06, 127.46,
127.80, 128.57, 133.86, 153.12, 164.73. HRMS: C27H27NO5Na requires 468.1787; Found 468.1785
(M++Na).
4-(4-Methoxyphenyl)-3-phenyl-1-(3,4,5-trimethoxybenzyl)azetidin-2-one 37. Preparation was from 24 as
described in method I. Yield 7.3 %, Clear oil. IR νmax (NaCl film): 1751.30cm-1 (C=O, β-lactam). 1H
NMR (400 MHz, CDCl3) δ 3.79 (m, 6H, OCH3), 3.85 (s, 6H, OCH3), 4.22 (d, 1H, J=2 Hz), 4.36 (d, 1H,
J=2 Hz), 4.88 (d, 1H, J=15.0 Hz), 6.41 (s, 2H), 6.96 (d, 2H, J=8.4 Hz), 7.17 – 7.31 (m, 11H, ArH). 13C
NMR (400 MHz, CDCl3) δ 21.49, 44.75, 55.39, 56.03, 60.88, 62.80, 65.03, 105.31, 114.50, 125.32,
127.33, 127.69, 127.93, 128.25, 128.92, 129.06, 131.34, 135.18, 137.32, 137.87, 153.43, 159.98,
168.45. HRMS: C26H27NO5Na requires 456.1787; Found 456.1798 (M++Na).
4.1.2.3 Reformatsky microwave reaction (method III) for preparation of 4-(4-ethoxyphenyl)-3phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 26. Zinc dust (6.9 mmol) was placed in 10 mL
microwave vial and 5 mL of anhydrous benzene was added and the vial capped. TMCS (0.325 mL) was
added. The reaction was stirred at 25°C, 50 W, for 15 mins and then heated at 100°C, 200W for 3 mins.
The vessel was allowed to cool before addition of N-(4-ethoxybenzylidene)-3,4,5-trimethoxyaniline 14
(5 mmol) and ethyl-α-bromophenylacetate (6 mmol). Reaction was carried out at 100°C, 200 W, 30
mins. It was then poured over 20 mL of saturated NH4Cl and 20 mL of 25 % NH4OH. CH2Cl2 (20 mL)
is used to extract the organic layer which is further washed with 20 mL 0.1 N HCl and 20 mL of water.
The organic layer is separated and dried using anhydrous sodium sulphate. 4-(4-Ethoxyphenyl)-3-phenyl1-(3,4,5-trimethoxyphenyl)azetidin-2-one 26 was obtained in 7 % yield as a white crystalline material,
m.p. 109 ºC. IR νmax (KBr): 1754.92 cm-1 (C=O, β-lactam). 1H NMR (400 MHz, CDCl3) δ 1.41 – 1.44
(t, 3H, CH2), 3.72 (s, 6H, OCH3), 3.77 (s, 3H, OCH3), 4.28 (d, 1H, J= 2 Hz, H3), 4.86 (d, 1H, J=2 Hz,
H4), 6.60 (s, 2H, ArH), 6.93 (d, 2H, J=8.52 Hz), 7.32 – 7.40 (m, 7H). 13C NMR (100 MHz, CDCl3) δ
14.35, 55.56, 60.51, 63.13, 63.43, 64.58, 94.39, 114.74, 126.88, 126.98, 127.43, 128.58, 128.68, 133.31,
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134.00, 134.36, 146.43, 153.05, 158.90, 165.22. HRMS: C26H27NO5Na requires 456.1787; Found
456.1800 (M++Na).
4.1.2.4 General method for synthesis of 4-diphenyl substituted β-lactams 38, 39 and 40
TiCl4 (2.0 mmol, 1M in CH2Cl2) was added to a solution of the appropriately substituted benzophenone
(4.0 mmol) and trimethoxyaniline (4.0 mmol) in anhydrous toluene (40 mL). Tri-n-butylamine (12.2
mmol) was added. The resulting mixture was stirred overnight under nitrogen. Tri-n-butylamine (8.4
mmol) and phenylacetyl chloride (4.4 mmol) were added sequentially. The mixture was brought to
reflux and refluxed for 8 hours. The mixture was cooled to room temperature, the reaction was quenched
with water, and the mixture was transferred to a separating funnel, diluted with ethyl acetate, washed
with 1M HCl, saturated NaHCO3, water, and brine, dried over anhydrous sodium sulfate and purified
using flash column chromatography over silica gel (eluent: hexane/ethyl gradient).

3,4,4-Triphenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one

38.

Preparation

was

as

above

from

benzophenone. Yield 0.4%, Yellow powder, m.p. 165 ºC. IR νmax (KBr): 1749.57 cm-1 (C=O, β-lactam).
1H

NMR (400 MHz, CDCl3) δ 3.60 (s, 6H, OCH3), 3.79 (s, 3H, OCH3), 5.18 (s, 1H, H3), 6.65 (s, 2H,

ArH), 6.90 – 6.92 (m, 2H, ArH), 7.03 – 7.13 (m, 8H, ArH), 7.38 – 7.41 (m, 3H, ArH), 7.60 – 7.62 (m,
2H, ArH).

13C

NMR (100 MHz, CDCl3) δ 55.88, 60.93, 72.44, 73.31, 95.97, 127.27, 127.46, 127.56,

127.94, 128.09, 128.50, 128.87, 129.21, 129.57, 132.79, 133.96, 134.21, 135.43, 140.56, 153.10,
166.61. HRMS: C30H27NO4Na requires 488.1838; Found 488.1856 (M++Na).
4-(4-Methoxyphenyl)-3,4-diphenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 39. Preparation was as
above from (4-methoxyphenyl)phenylmethanone. Yield 20 %, White powder, m.p. 171 ºC. IR νmax
(KBr): 1742.06 cm-1 (C=O, β-lactam). 1H NMR (400 MHz, CDCl3) δ 3.63 (s, 6H, OCH3), 3.80 (s, 3H,
OCH3), 3.84 (s, 3H, OCH3), 5.16 (s, 1H, H3), 6.69 (s, 2H, ArH), 6.88 – 6.96 (m, 4H, ArH), 7.03 – 7.15
(m, 7H, ArH), 7.38 – 7.44 (m, 1H, ArH), 7.60 (d, 2H, J=8.8 Hz, ArH). 13C NMR (100 MHz, CDCl3) δ
54.94, 55.45, 60.48, 72.02, 72.72, 95.50, 112.36, 113.62, 126.74, 126.97, 127.04, 127.40, 127.62,
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127.70, 127.94, 128.38, 128.68, 128.87, 129.09, 129.94, 131.83, 132.44, 133.54, 133.72, 133.32,
152.64, 159.09, 166.26.
4,4-Bis-(4-methoxyphenyl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 40. Preparation was as
above from bis-(4-methoxyphenyl)methanone. Yield 17 %, White powder, m.p. 165 ºC. IR νmax (KBr):
1742.60 cm-1 (C=O, β-lactam). 1H NMR (400 MHz, CDCl3) δ 3.63 (s, 6H, OCH3), 3.73 (s, 3H, OCH3),
3.80 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 5.12 (s, 1H, H3), 6.63 (d, 2H, J=8.8 Hz), 6.68 (s, 2H, ArH),
6.90 – 6.95 (m, 6H, ArH), 7.09 – 7.11 (s, 3H, ArH), 7.51 (d, 2H, J=9.28 Hz, ArH). 13C NMR (100 MHz,
CDCl3) δ 54.72, 54.94, 55.45, 60.48, 71.86, 72.31, 95.48, 112.31, 113.57, 127.04, 127.35, 127.67,
128.79, 129.08, 129.85, 132.22, 132.50, 133.55, 152.62, 158.05, 159.00, 166.34. HRMS: C32H31NO6Na
requires 548.2049; Found 548.2062 (M++Na).
4.2 Biochemical evaluation of activity
4.2.1 Antiproliferative studies. All assays were performed in triplicate for the determination of mean
values reported. Compounds were assayed as the free bases isolated from reaction. The human breast
tumour cell line MCF-7 was cultured in Eagles minimum essential medium in a 95%O2/5% CO2
atmosphere with 10% fetal bovine serum, 2mM L-glutamine and 100 µg/mL penicillin/streptomycin.
The medium was supplemented with 1% non-essential amino acids. MDA-MB-231 cells were
maintained in Dulbecco’s Modified Eagle’s medium (DMEM), supplemented with 10% (v/v) Fetal
bovine serum, 2mM L-glutamine and 100 µg/mL penicillin/streptomycin (complete medium). Cells
were trypsinised and seeded at a density of 2.5 x 104 cells/mL in a 96-well plate and incubated at 37oC,
95%O2/5% CO2 atmosphere for 24 h. After this time they were treated with 2 µL volumes of test
compound which had been pre-prepared as stock solutions in ethanol to furnish the concentration range
of study, 1 nM–100 µM, and re-incubated for a further 72 h. Control wells contained the equivalent
volume of the vehicle ethanol (1% v/v). The culture medium was then removed and the cells washed
with 100 µL phosphate buffered saline (PBS) and 50 µL MTT added, to reach a final concentration of 1
mg/mL MTT added. Cells were incubated for 2 h in darkness at 37oC. At this point solubilization was
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begun through the addition of 200 µL DMSO and the cells maintained at room temperature in darkness
for 20 min to ensure thorough colour diffusion before reading the absorbance. The absorbance value of
control cells (no added compound) was set to 100 % cell viability and from this graphs of absorbance
versus cell density per well were prepared to assess cell viability and from these, graphs of percentage
cell viability versus concentration of subject compound added were drawn.
4.2.2 Cytotoxicity. Cytotoxicity was determined using the CytoTox 96 non-radioactive cytotoxicity
assay by Promega following the manufacturer’s protocol [39]. The assay quantitatively measures lactate
dehydrogenase (LDH) a stable cytosolic enzyme that is released upon cell lysis. Released LDH in
culture supernatant is measured in a 30 minute coupled enzymatic assay, which results in the conversion
of a tetrazolium salt (INT) into a red formazan product [40].
MCF-7 and MDA-MB-231 cells were seeded in 96-well plates, incubated for 24 hours and then treated
with compounds as described for the antiproliferative assay above. After 72 hours, 20 μL of lysis
solution (10X) was added to the ‘blank’ wells and left for 1 hour to ensure 100 % death. 50 μL was
removed from each well and transferred to a new 96-well plate. 50 μL of substrate mix from the LDH
assay kit was added and the plate was incubated in the dark at room temperature for 30 minutes. After
this period, 50 μL of stop solution was added to each well before reading the absorbance at a wavelength
of 490 nm using a Dynatech MR5000 plate reader. Percentage cell death was calculated at 10 μM.
4.2.3 Tubulin polymerisation assay. The effect of a selected analogue 26 on the polymerisation of
purified bovine brain tubulin was determined spectrophotometrically by monitoring the change in
turbidity. Lyophilised tubulin (Cytoskeleton, Denver, CO) was re-suspended in ice cold G-PEM buffer
(80 mM PIPES pH 6.9, 0.5 mM MgCl2, 1 mM EGTA, 1 mM GTP, 10.2% (v/v) glycerol) and added to
wells on a half volume 96 well plate containing the designated concentration of drug (10 µM) or vehicle.
Samples were mixed well and tubulin assembly was monitored at A340 nm at 30 sec intervals for 60 min at
37 oC in a Spectramax 340PC spectrophotometer (Molecular Devices).
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4.2.4 Immunofluorescence and confocal microscopy. For immunofluorescence, MCF-7 cells were
seeded at 1x105 per well on BD falcon four well chamber glass slides (BD Biosciences, San Jose, USA.
Cells were treated with vehicle [1% ethanol (v/v)], 4 [100 nM], 26 [500 nM] for 16 h. Following
treatment cells were washed gently in PBS, permabilised with PBS and 0.1% Triton-X-100, fixed for 30
min in methanol at -20oC. Following washes in PBS cells were blocked in 5% BSA diluted in PBST
(blocking buffer). Cells were then incubated with mouse anti-tubulin (DM1A (Merck Chemicals Ltd);
1:20 for 1 h at room temperature. Following washes in PBST cells were incubated with fluorescein
isothiocyanate (FITC) conjugated rabbit anti-mouse (Dakocytomation, UK); 1:200 for 1 h at room
temperature. Following washes in PBST, the cells were mounted in Ultra Cruz Mounting Media (Santa
Cruz Biotechnology, Santa Cruz, CA) containing 4,6-diamino-2-phenolindol dihydrochloride (DAPI).
Confocal images were captured using the OLYMPUS 1X81 microscope coupled with OLYMPUS
FLUOVIEW Ver 1.5 software. All images in each experiment were collected on the same day using
identical parameters.
4.2.5 Determination of DNA content by flow cytometry. MCF-7 cells were seeded at 5 x 105 cells/mL
in T25 flasks. After 24 h, cells were treated with vehicle [1% ethanol (v/v)], 4 [100 nM] or 26 [500 nM]
for 48 h. Cells were harvested by centrifugation at 800 x g for 10 min. Cell pellets were resuspended in
PBS and fixed in 70 % ethanol: PBS overnight at -20 oC. Following centrifugation cell pellets were resuspended in PBS supplemented with 0.5 mg/mL RNase and 0.15 mg/mL propidium iodide (PI).
Following a 30 min incubation at 37oC in the dark the PI fluorescence was measured on a linear scale
using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA). The amount of PI fluorescence
is directly proportional to the amount of DNA present in each cell. The relative content of DNA
indicates the distribution of a population of cells throughout the cell cycle. For example, cells in G 0G1
are diploid and have a DNA content of 2N. Cells with the G2M phases have a DNA content of 4N, while
cells in S-phase have a DNA content between 2N and 4N. Apoptotic cells are sub-diploid (<2N). Data
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collection was gated to exclude cell debris and cell aggregates. At least 10,000 cells were analysed per
sample. All data were recorded and analysed using the CellQuest software (Becton Dickinson).
4.3 X-ray crystallography. The X-ray crystallography data for compound 26 was collected on a Rigaku
Saturn 724 CCD Diffractometer. A suitable crystal was selected and mounted on a glass fiber tip and
placed on the goniometer head in a 123K N2 gas stream. The data set was collected using CrystalclearSM 1.4.0 software and 1680 diffraction images, of 0.5° per image, were recorded. Data integration,
reduction and correction for absorption and polarization effects were all performed using CrystalclearSM 1.4.0 software. Space group determination, structure solution and refinement were obtained using
Crystalstructure ver. 3.8 and Bruker Shelxtl Ver. 6.14 software.[41] Crystal Data for 26:
C208H216N8O40, MW3469.89 (unit cell), Monoclinic, Space group C2/c; a = 20.90(3), b = 17.62(2), c =
14.02(2)A˚, β = 119.95(5); U = 4474(12)(Å)3; Z = 1; Dc = 1.287 Mg m-3; m = 0.089 mm-1; Range for
data collection = 2.12–25.00; Reflections collected 16136 , Unique Reflections 3934 [Rint = 0.165];
Data/restraints/parameters 3934/0/294; Goodness-of-fit on F2 1.194; R indices (all data) = R1 = 0.0746,
wR2 = 0.1678; Final R indices [I > 2s(I)] = R1 = 0.0646, wR2 = 0.1596. Cambridge Crystallographic
Data Centre (CCDC ID: 815023).
4.4 Molecular modeling. PDB entry 1SA0 [36] was downloaded and only chains A and B with cocrystallised N-deacetyl-N-(2-mercaptoacetyl)-colchicine (DAMA-colchicine, 41) were retained. The Xray co-ordinates of compound 26 were used as input for a docking simulation carried out using Molegro
Virtual Docker [42]. A search space of 15Å around colchicine was created and the binding site defined
by cavity detection within Molegro. No docking template was used to prevent search bias. A grid
resolution of 0.30Å and searching and scoring using MolDock score was enabled for 10 runs. All other
parameters were kept as default and 10 poses were generated for each run. The top scoring docked
solution was retained for analysis in MOE [43].
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Figure, Scheme and Table Legends
Figure 1. Tubulin binding agents
Figure 2. Heterocyclic analogues of 4
Figure 3. Ortep representation of the crystal structure of 26 with displacement ellipsoids plotted at 50%
Figure 4. Tubulin polymerization for 26 (blue squares) and ethanol (vehicle control, red squares)
Effects of compound 26 (10 µM) on in vitro tubulin polymerisation. Purified bovine tubulin and GTP
were mixed in a 96-well plate. The reaction was started by warming the solution from 4 oC to 37oC.
Ethanol (1%v/v) was used as a vehicle control. The effect on tubulin assembly was monitored in a
Spectramax 340PC spectrophotometer at 340nm at 30 second intervals for 60 minutes at 37 oC. The
graph shows one representative experiment. Each experiment was performed in triplicate.
Figure 5: CA-4 (4) and β-lactam 26 depolymerise the microtubule network of MCF-7 cells resulting in
mitotic catastrophe.
MCF-7 cells were treated with vehicle [1% ethanol (v/v)], CA-4 (4) [100 nM] or 26 (500 nM) for 16 h.
Cells were fixed in methanol and stained with α-tubulin mAbs (green) and counterstained with DAPI
(red). Images were captured by confocal microscopy coupled with OLYMPUS FLUOVIEW software.
Bar equal to 40 µm. Representative confocal micrographs of three separate experiments are shown.
Figure 6: Effect of 4 and 26 on the cell cycle.
MCF-7 cells were left untreated (U) or treated with vehicle (V) [1% ethanol (v/v)], CA-4 (4) [100 nM],
26 [500 nM] for 48 h. Percentages of (A) G2M arrested cells and (B) apoptotic (sub-G1) are indicated.
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Values represent the mean ± SEM for at least three separate experiments. *, P < 0.05. C, representative
DNA profiles are shown and mean percentage of cells in sub-G1 and G2M are indicated.
Figure 7. The crystal structure of tubulin with (A) DAMA-colchicine 41 and (B) docked X-ray of
compound 26 in the same active site
Docked pose of 41 and β–lactam 26 in the colchicine binding site of tubulin (PDB entry 1SA0).
Hydrogens are not shown for clarity. Coloured by atom: Green (colchicine carbon); Pink (β-lactam
carbon); red (oxygen); blue (nitrogen). Residue numbers are those used by Ravelli et al[36].
Figure 8. Distances between the centres of the three phenyl rings of β-lactam 26 (single crystal X-ray
structure).
Scheme 1a*
a

Reagents and conditions: (a) Ethanol, reflux, 3 hours; (b) Method I: C6H5CH2COCl, (CH3CH2)3N,

CH2Cl2, 3 hours, reflux; (c) Method II: C6H5CH2COCl, (CH3CH2)3N, triphosgene, CH2Cl2, overnight;
(d) Method III: Ethyl-α-bromophenylacetate, zinc, TMCS, benzene, microwave
*Only one enantiomer of β-lactam compounds illustrated for clarity
Scheme 2: Preparation of β-lactams 35, 36 and 37 via the Staudinger reaction a*
a

Reagents and conditions: (a) Ethanol, reflux, 3 h; (b) C6H5CH2COCl, (CH3CH2)3N, CH2Cl2, reflux, 3

h
*Only one enantiomer of β-lactam compounds illustrated for clarity
Scheme 3: Preparation of 4,4-diphenyl substituted β-lactams 38 - 40 a
aReagents

and conditions: (a) TiCl4, anhydrous toluene, tri-n-butylamine, 18 h (b) Tri-n-butylamine,

C6H5CH2COCl, reflux, 8 h
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Table 1. Antiproliferative effects of combretastatin β-lactam analogues 26 - 40 in MCF-7 cells
aIC

50

values are half maximal inhibitory concentrations required to block the growth stimulation of

MCF-7 cells. Values represent the mean ± S.E.M (error values x 10-6) for at least three experiments
performed in triplicate.
bThe

IC50 value obtained for 4 in this assay is 0.005 µM for MCF-7 which is in good agreement with the

reported values for 4 using the MTT assay on human MCF-7 breast cancer cell line[35, 44-46]
Table 2. Antiproliferative effects of combretastatin β-lactam analogues in MDA-MB-231 cells
aIC

50

values are half maximal inhibitory concentrations required to block the growth stimulation of

MDA-MB-231 cells. Values represent the mean ± S.E.M (error values x 10-6) for at least three
experiments performed in triplicate.
bThe

IC50 value obtained for 4 in this assay is 0.043 µM for MDA-MB-231 which is in good agreement

with the reported values for 4 using the MTT assay on the human MDA-MB-231 breast cancer cell
line[47, 48]
Table 3: Flow cytometric analysis of both cell death (sub-G1) and the cell cycle in MCF-7 cells exposed
to 4 and β-lactam 26a
aCell

cycle analysis of MCF-7 cells untreated or treated with vehicle control (1 % (v/v) ethanol), 4

(100nM) or 26 (500nM) for 48 hours. % MCF-7 cells in each cell cycle phase are shown after exposure
to compounds 4 or 26 for 48 hours. Cells were analysed with the FACScan flow cytometry. Cells in the
sub-G1 peak are indicative of apoptotic cells. Results show a typical experiment which has been
repeated three times. Values represent the mean ± standard deviation for three experiments.
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